International Journal of Rheumatic Diseases最新文献

{"title":"Exploring the Link Between Genetic Predictors of Systemic Lupus Erythematosus and Epstein–Barr Virus Infections","authors":"Yanying Piao, Lei Li, Rongxian An, Dinglu Cui, Xinying Cui, Long Jiang, Jingchun Jin","doi":"10.1111/1756-185X.70067","DOIUrl":"https://doi.org/10.1111/1756-185X.70067","url":null,"abstract":"<p>Systemic lupus erythematosus (SLE) is one of the most common autoimmune diseases (ADs), has widespread clinical manifestations and a chronic relapsing–remitting course, and has different clinical courses and prognoses [<span>1, 2</span>]. The published data showed that AD patients have an increased danger of developing malignancies. According to relevant literature reports, viruses related to SLE include EBV, Parvovirus B19 (B19V), Retro viruses (RVs), Human Endogenous Retroviruses (HERV), Human Immunodeficiency Virus (HIV), Torque Teno Virus (TTV) and Cytomegalovirus (CMV) [<span>3</span>].</p><p>Epstein–Barr virus (EBV) is a lymphotripic virus, also known as Human Herpesvirus (HHV) 4 [<span>4</span>]. It is also considered as the most common human viruses and infects at least 90% of adults worldwide [<span>5</span>]. EBV is believed to be associated with the onset of a lot of ADs, such as rheumatoid arthritis (RA), multiple sclerosis (MS), and SLE [<span>6-8</span>].</p><p>Mendelian randomization (MR) analysis is a new-type epidemiological analysis method that uses instrumental variables (IVs) to analyze genetic variation and assess the causal association between exposures and outcomes [<span>9</span>]. The relevant IVs for MR research are from genome-wide association studies (GWAS).</p><p>The key point in conducting MR analysis was to select proper genetic variants from the open obtainable GWAS database as effective IVs. We selected single nucleotide polymorphisms (SNPs) from the IEU GWAS database (https://gwas.mrcieu.ac.uk/) and FinnGen database (http://www.finngen.fi) for IVs of all exposures, mediators, and outcomes. Instrumental SNPs were related with SLE and cancers at genome-wide relevance (<i>p</i> < 5e-8). Obtain genome-wide significant (<i>p</i> < 1e-5) IVs from five EBV infection databases to improve inference and computational abilities. Summary of data in this MR study can be seen in Table S1.</p><p>To make sure the facticity and correctness of the inferences regarding the causal relationship between EBV infections and SLE, we have implemented a series of quality control measures to select qualified IVs. We extracted genome-wide significantly correlated SNPs from the GWAS summary data, with linkage disequilibrium (LD) and independent (<i>r</i><sup>2</sup> = 0.001, kb = 10 000) SNPs for sorting. We followed the above steps to screen EBV infections, cancers, and SLE-related SNPs with significant correlation, linkage equilibrium, and independence from the GWAS database for MR analysis. We also estimated the <i>F</i>-statistic of SNPs to evaluate the strength of instrumental variables. If <i>F</i> > 10, it means that if the likelihood of instrumental variable bias is small, SNPs with <i>F</i>-statistic less than 10 should be removed.</p><p>In our study, the main statistical analysis was performed to use the R packages (version 4.3.2). Further, we used the “TwoSampleMR” (version 0.5.8) and “MR-PRESSO” (version 1.0) packages ","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 2","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70067","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143111196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Tocilizumab in Polymyalgia Rheumatica: A Systematic Review and Meta-Analysis","authors":"Meha Sharma,&nbsp;Siddharth Kumar Das,&nbsp;Ritin Mohindra,&nbsp;Deep Dutta","doi":"10.1111/1756-185X.70106","DOIUrl":"10.1111/1756-185X.70106","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>No meta-analysis has holistically analyzed and summarized the efficacy and safety of tocilizumab in polymyalgia rheumatica (PMR). We undertook this meta-analysis to address this knowledge-gap.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Electronic databases were searched for RCTs involving patients living with PMR receiving tocilizumab in intervention arm, and placebo/active comparator in control arm. Primary outcome was to evaluate percentage of patients able to achieve C-reactive protein PMR assessment score (CRP-PMR-AS) &lt; 10 or prednisolone dose &lt; 5 mg/day or &gt; 10 mg/dL decline in prednisolone from baseline. Secondary outcomes were to determine percentage of patients able to totally stop prednisolone and adverse-events.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>From initially screened 115 articles, data from 2 RCTs (136 patients) was analyzed. In addition, a descriptive analysis of 8 observational studies (356 patients) was also done. After 24-weeks of clinical use, patients with PMR receiving tocilizumab had significantly higher chances of achieving composite primary end-point defined as CRP-PMR-AS &lt; 10 and either prednisone dosage &lt; 5 mg/day or decrease in prednisolone dosage by &gt; 10 mg/day compared to baseline [odds ratio (OR) 4.89 (95% CI: 2.34–10.23); <i>p</i> &lt; 0.001; <i>I</i>² = 0%], compared to placebo. Patients with PMR receiving tocilizumab also had significantly higher chances of being able to stop prednisolone compared to placebo [OR 4.45 (95% CI: 2.06–9.61); <i>p</i> &lt; 0.001; <i>I</i>² = 0%]. Occurrence of total adverse-events [risk ratio (RR) 1.24 (95% CI: 0.50–3.12); <i>p</i> = 0.64; <i>I</i>² = 0%], adverse-events leading to treatment discontinuation [RR 0.45 (95% CI: 0.10–2.02); <i>p</i> = 0.29; <i>I</i>² = 17%], and infections [RR 1.71 (95% CI: 0.83–3.52); <i>p</i> = 0.14; <i>I</i>² = 6%] were comparable in patients receiving tocilizumab as compared to placebo. Observational studies have noted lung infections, neutropenia and increased cholesterol with tocilizumab use.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Tocilizumab is well tolerated and is effective for managing PMR. Tocilizumab is an effective glucocorticoid sparing agent in PMR.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 2","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetically Predicted Plasma Metabolome Mediates the Causal Link Between Immune Cells and Risk of Gout","authors":"Yi Wei,&nbsp;Jiangyi Yu","doi":"10.1111/1756-185X.70094","DOIUrl":"10.1111/1756-185X.70094","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Gout is a prevalent metabolic disorder characterized by a multifaceted process of development. Recent research has emphasized a robust correlation between the immune response and gout. Nevertheless, it is still uncertain if this connection is causative. Hence, the objective of this study was to investigate the causal relationship between immune cells and gout, while also analyzing the role of the plasma metabolome as metabolic mediators in this biological process.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study explored the causal link between different subtypes of immune cells and gout using two-sample Mendelian randomization (MR). To confirm the reliability of the findings, reverse MR analysis, steiger test and sensitivity tests were conducted. A two-step mediation analysis was used to gain insight into the role of plasma metabolites as intermediate mediators.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This two-sample, bidirectional, two-step MR analysis found a nominal causal link between 33 immune cells as well as 47 known plasma metabolites and gout. Reverse MR analysis and sensitivity tests demonstrated the reliability of the MR results. In addition, we found that Tetradecadienedioate (C14:2-DC) played a partially mediating role in the CD4 on activated CD4 regulatory T cell and gout pathways, with a mediating proportion of 13.16%, (95% CI = 0.65%–25.67%, <i>p</i> = 0.034).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The objective of our research was to investigate the possible causative connection between immune cells and gout. Our findings indicate that certain plasma metabolites may play a role in mediating this association. This study offers novel insights and sources of information that may contribute to the early detection and proactive measures to avoid gout in the future.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 2","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduced Health-Related Quality of Life in Patients With Systemic Sclerosis: A Cross-Sectional Analysis of PROMIS Global Health Data From the International COVAD-2 e-Survey","authors":"Keina Yomono,&nbsp;Yuan Li,&nbsp;Vahed Maroufy,&nbsp;Naveen Ravichandran,&nbsp;Akira Yoshida,&nbsp;Kshitij Jagtap,&nbsp;Tsvetelina Velikova,&nbsp;Parikshit Sen,&nbsp;Lorenzo Cavagna,&nbsp;Vishwesh Agarwal,&nbsp;Johannes Knitza,&nbsp;Ashima Makol,&nbsp;Dzifa Dey,&nbsp;Carlos Enrique Toro Gutiérrez,&nbsp;Tulika Chatterjee,&nbsp;Aarat Patel,&nbsp;Latika Gupta,&nbsp;Vikas Agarwal,&nbsp;Masataka Kuwana,&nbsp;COVAD study group","doi":"10.1111/1756-185X.70101","DOIUrl":"10.1111/1756-185X.70101","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 2","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal Association Between Chronic Inflammatory Arthropathies and Sarcopenia and the Mediation Role of Inflammatory Factors","authors":"Yanyan Qian,&nbsp;Xiaowei Wang,&nbsp;Chen Zhu,&nbsp;Qiang Tong,&nbsp;Jianzheng Zhang,&nbsp;Shengjie Zhao","doi":"10.1111/1756-185X.70100","DOIUrl":"10.1111/1756-185X.70100","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Although chronic inflammatory arthropathies (CIA) are associated with sarcopenia, sarcopenia plays a role in their pathogenesis remains unknown. This study investigated the causal relationship between sarcopenia and CIA and to identify potential mediating factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We examined data from 458 910 participants in the UK Biobank to analyze the association between sarcopenia-related traits and CIA. Associations between hand-grip strength, muscle mass, walking pace, and CIA were analyzed using Cox regression models. Then, we performed a mediation analysis to explore the underlying mechanisms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Individuals with low hand-grip strength exhibited a 1.88-fold (95% CI 1.73–2.05), 2.22-fold (95% CI 2.02–2.45), and 1.36-fold (95% CI 1.32–1.41) increased risk of rheumatoid arthritis (RA), spondyloarthritis (SpA), and osteoarthritis (OA), respectively. The HRs for sarcopenia were 1.64 (95% CI 1.15–2.32) for RA, 1.83 (95% CI 1.21–2.77) for SpA, and 1.26 (95% CI 1.09–1.45) for OA. Additionally, individuals with a slow walking pace exhibited a 1.83-fold (95% CI 1.66–2.02), 3.58-fold (95% CI 3.25–3.95), and 1.82-fold (95% CI 1.77–1.88) increased risk of RA, SpA, and OA, respectively. Furthermore, we identified inflammatory markers as possible mediators of the causal effects of low hand-grip strength on the development of CIA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our findings suggest that sarcopenia is independently associated with an increased risk of CIA, which is partially mediated by inflammation factors.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 2","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epstein–Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in a Patient With Behçet's Disease Treated With Adalimumab","authors":"Shuya Kaneko,&nbsp;Dan Tomomasa,&nbsp;Maho Hatano,&nbsp;Hitoshi Irabu,&nbsp;Yuko Hayashi,&nbsp;Hirokazu Kanegane,&nbsp;Masaki Shimizu","doi":"10.1111/1756-185X.70107","DOIUrl":"10.1111/1756-185X.70107","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 2","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychometric Properties of the Chinese Version of the Arthritis Self-Care Behaviors Scale","authors":"Jieqing Ni,&nbsp;Mingming Zhang,&nbsp;Anqi Xu,&nbsp;Huiling Hu,&nbsp;Bilin Wu,&nbsp;Xue Wu","doi":"10.1111/1756-185X.70078","DOIUrl":"10.1111/1756-185X.70078","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In Chinese intervention studies, the lack of specific self-care scales based on the functional characteristics of Rheumatoid arthritis (RA) patients has caused patients and researchers to spend a great deal of time completing multiple related scales during the research work. Therefore, the arthritis Self-Care Behaviors Scale (SCBS) was developed to evaluate the self-care behavior of patients with arthritis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The objectives of this study were to translate the SCBS into Chinese and test its psychometric properties in Chinese patients with RA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The SCBS (English version) was translated to Chinese using Brislin's forward and backward translation method. A total of 414 adults with RA completed the Chinese version of the SCBS. Item analysis, content validity, construct validity, internal consistency reliability, and test–retest reliability were used to test its psychometric properties.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Item analysis showed that the SCBS (Chinese version) has good discrimination and consistency. The Cronbach's alpha coefficient was 0.873 of the content validity index (CVI). Exploratory factor analysis demonstrated a five-factor solution, which is different from the traditional one. The results of the five common factor models indicated that the revised Chinese version of SCBS had good construct validity. The test–retest coefficient was 0.82, supporting adequate reliability.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The Chinese version of the SCBS is a reliable and valid instrument to evaluate RA patients' self-care behavior in China. However, further research into different economic levels, education levels, and age groups would broaden the scope of the Chinese version of the SCBS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling the Genetic Link: Exploring the Causal Relationship Between Periodontitis and Allergic Rhinitis","authors":"Siwei Liu,&nbsp;Xufeng Huang,&nbsp;Longbin Wang,&nbsp;Zhengrui Li","doi":"10.1111/1756-185X.70011","DOIUrl":"10.1111/1756-185X.70011","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infections in Idiopathic Inflammatory Myopathies: Do Asians Need a Different Dose of Immunosuppression?","authors":"Jasmine Parihar,&nbsp;Takahisa Gono,&nbsp;Ho So,&nbsp;Latika Gupta,&nbsp;the APLAR myositis SIG","doi":"10.1111/1756-185X.70084","DOIUrl":"10.1111/1756-185X.70084","url":null,"abstract":"&lt;p&gt;Day et al. highlight the intricate challenges in managing rare rheumatic diseases like idiopathic inflammatory myopathies (IIMs), particularly when aggressive immunosuppression is complicated by opportunistic infections [&lt;span&gt;1&lt;/span&gt;]. This rare disease-rare complication scenario is further complicated by the hypothesis that infections may trigger autoimmunity, creating a paradoxical management dilemma. Opportunistic infections, which often present atypically in myositis patients and may mimic active IIM, pose a significant clinical challenge [&lt;span&gt;2&lt;/span&gt;]. Furthermore, infections are the leading cause of death in myositis patients, suggesting that clinicians need to manage the prevention and early detection of infection. Moreover, immunosuppressive drugs (ISDs) may lead to other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPDs), particularly in patients treated with methotrexate [&lt;span&gt;3&lt;/span&gt;]. The absence of well-defined guidelines for these complex scenarios underscores the urgent need for comprehensive research to inform evidence-based management strategies in these challenging cases.&lt;/p&gt;&lt;p&gt;In patients with IIM and other autoimmune diseases, infection risk is influenced by a complex interplay of disease characteristics and treatment. A dysregulated immune response, disease severity, and the use of immunosuppressive medications significantly increase infection risk in conditions such as systemic lupus erythematosus (SLE) with an infection rate of 29.2%–43.9% [&lt;span&gt;4&lt;/span&gt;]. Opportunistic infections in myositis patients also present a significant clinical challenge, with a reported 33%–54% overall infection rate and 6%–12% classified as opportunistic, particularly within the first year of high-dose corticosteroid treatment [&lt;span&gt;5-7&lt;/span&gt;]. Dermatomyositis patients, especially those with anti–MDA5-antibody positivity, face heightened infection risks independent of immunosuppressive therapy [&lt;span&gt;7-9&lt;/span&gt;]. Other factors, such as methylprednisolone pulse therapy, combination therapy, disease onset after age 50 years, a lymphocyte count below 1200/mm&lt;sup&gt;3&lt;/sup&gt;, high serum KL-6 levels, and the presence of interstitial lung disease (ILD), also contribute to higher infection risk [&lt;span&gt;10, 11&lt;/span&gt;]. This issue is particularly acute in developing regions like Asia, where environmental factors and healthcare disparities, including inadequate vaccination protocols for immunosuppressed patients, exacerbate outcomes. The prevalence and impact of these infections underscore the urgent need for improved prevention strategies and management guidelines, especially in resource-limited settings.&lt;/p&gt;&lt;p&gt;Significant regional disparities in infection prevalence among myositis patients demand tailored management strategies. Asia reports higher mycobacterial infection rates (5.86%) compared to Europe (2.36%) and Latin America (2.47%) in IIM patients [&lt;span&gt;12&lt;/span&gt;]. These patients show increased susceptibility t","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70084","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143038849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kawasaki Disease Can Come Calling as Aphon(e)ia: Laryngeal Weakness as the Presentation of Myositis in Kawasaki Disease","authors":"Gayathri Coimbatore Vaitheeswaran,&nbsp;Anirban Basu,&nbsp;Prabal Barman,&nbsp;Ridhima Aggarwal,&nbsp;Rakesh Kumar Pilania","doi":"10.1111/1756-185X.70091","DOIUrl":"10.1111/1756-185X.70091","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143038850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}